NCT00679718
Completed
Phase 2
A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution vs. Placebo in Patients With Moderate to Severe Dry Eye Disease
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Dry Eye Disease
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 150
- Primary Endpoint
- Change in artificial tear usage
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
To evaluate the efficacy and safety of INS365 Ophthalmic Solution when applied topically in patients with moderate to severe dry eye disease.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Best corrected visual acuity of at least +0.7 ETDRS
- •Six month history of dry eye disease
- •Mild severity in two out of five symptoms
- •Unanesthetized Schirmer score of less than or equal to 7mm
- •Corneal fluorescein staining greater than or equal to 4 out of 15 or lissamine green conjunctival staining of greater than or equal to 5 out of 18
Exclusion Criteria
- •Nasal stimulated Schirmer score of less than 3mm
- •Have ongoing ocular infection
- •Have congenitally absent meibomian or lacrimal glands
- •Have had punctal occlusion within a specified time prior to study
- •Wear contact lens and refuse to remove them
- •Have other excluded eye conditions.
Outcomes
Primary Outcomes
Change in artificial tear usage
Schirmer scores
Corneal staining
Conjunctival staining
Tear break-up time
Patient-reported improvement of foreign body sensation
Secondary Outcomes
- Visual acuity
- Investigator global severity assessment
- Patient-reported dry eye symptoms other than foreign body sensation
- Biomicroscopy
- Ophthalmoscopy
- IOP
Similar Trials
Completed
Phase 3
Study of INS365 Ophthalmic Solution in Subjects With Dry Eye DiseaseDry Eye DiseaseNCT00404131Merck Sharp & Dohme LLC500
Completed
Phase 3
Study of INS365 Ophthalmic Solution in Subjects With Dry Eye DiseaseDry Eye DiseaseNCT00403715Merck Sharp & Dohme LLC500
Completed
Phase 2
A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic SolutionDry Eye DiseaseNCT00680108Merck Sharp & Dohme LLC62
Completed
Phase 1
A Placebo-Controlled Study of INS117548 Ophthalmic Solution in Subjects With Glaucoma (P08650)GlaucomaNCT00767793Merck Sharp & Dohme LLC84
Completed
Phase 3
Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry EyeKeratoconjunctivitis SiccaNCT00037661Merck Sharp & Dohme LLC222